Advertisement

Molecular Virology and Life Cycle

  • Darren J. Wong
  • Stephen A. LocarniniEmail author
Chapter

Abstract

The hepatitis B virus is a prevalent human infection with no cure at present. It is a significant cause of global morbidity and mortality and has achieved its persistence in humans via its complex life cycle and ability to use its few protein products in a multifunctional manner to subvert and evade immune detection and clearance. These aspects of the virus are discussed in detail, as are the development of clinically important mutations in the viral genome that develop as a result of host immune selection, as well as those selected by the introduction of antiviral therapy or vaccination.

Keywords

Hepatitis B Molecular Virology Lifecycle Antiviral Resistance 

References

  1. Amini-Bavil-Olyaee S, Herbers U, Sheldon J, Luedde T, Trautwein C, Tacke F. The rtA194T polymerase mutation impacts viral replication and susceptibility to tenofovir in hepatitis B e antigen-positive and hepatitis B e antigen-negative hepatitis B virus strains. Hepatology. 2009;49(4):1158–65.PubMedCrossRefGoogle Scholar
  2. Angus P, Vaughan R, Xiong S, Yang H, Delaney W, Gibbs C, et al. Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology. 2003;125(2):292–7.PubMedCrossRefGoogle Scholar
  3. Bartenschlager R, Schaller H. Hepadnaviral assembly is initiated by polymerase binding to the encapsidation signal in the viral RNA genome. EMBO J. 1992;11(9):3413–20.PubMedPubMedCentralGoogle Scholar
  4. Bartholomeusz A, Schaefer S. Hepatitis B virus genotypes: comparison of genotyping methods. Rev Med Virol. 2004;14(1):3–16.PubMedCrossRefGoogle Scholar
  5. Bartholomeusz A, Tehan BG, Chalmers DK. Comparisons of the HBV and HIV polymerase, and antiviral resistance mutations. Antivir Ther. 2004;9(2):149–60.PubMedGoogle Scholar
  6. Beck J, Nassal M. Hepatitis B virus replication. World J Gastroenterol. 2007;13(1):48–64.PubMedPubMedCentralCrossRefGoogle Scholar
  7. Belloni L, Pollicino T, De Nicola F, Guerrieri F, Raffa G, Fanciulli M, et al. Nuclear HBx binds the HBV minichromosome and modifies the epigenetic regulation of cccDNA function. Proc Natl Acad Sci U S A. 2009;106(47):19975–9.PubMedPubMedCentralCrossRefGoogle Scholar
  8. Benhenda S, Ducroux A, Riviere L, Sobhian B, Ward MD, Dion S, et al. Methyltransferase PRMT1 is a binding partner of HBx and a negative regulator of hepatitis B virus transcription. J Virol. 2013;87(8):4360–71.PubMedPubMedCentralCrossRefGoogle Scholar
  9. Bertoletti A, Chisari FV, Penna A, Guilhot S, Galati L, Missale G, et al. Definition of a minimal optimal cytotoxic T-cell epitope within the hepatitis B virus nucleocapsid protein. J Virol. 1993;67(4):2376–80.PubMedPubMedCentralGoogle Scholar
  10. Bock CT, Schranz P, Schroder CH, Zentgraf H. Hepatitis B virus genome is organized into nucleosomes in the nucleus of the infected cell. Virus Genes. 1994;8(3):215–29.PubMedCrossRefGoogle Scholar
  11. Bock CT, Schwinn S, Locarnini S, Fyfe J, Manns MP, Trautwein C, et al. Structural organization of the hepatitis B virus minichromosome. J Mol Biol. 2001;307(1):183–96.PubMedCrossRefGoogle Scholar
  12. Bock CT, Tillmann HL, Torresi J, Klempnauer J, Locarnini S, Manns MP, et al. Selection of hepatitis B virus polymerase mutants with enhanced replication by lamivudine treatment after liver transplantation. Gastroenterology. 2002;122(2):264–73.PubMedCrossRefGoogle Scholar
  13. Brunelle M-N, Jacquard A-C, Pichoud C, Durantel D, Carrouee-Durantel S, Villeneuve J-P, et al. Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir. Hepatology. 2005;41(6):1391–8.PubMedCrossRefGoogle Scholar
  14. Bruss V. Hepatitis B virus morphogenesis. World J Gastroenterol. 2007;13(1):65–73.PubMedPubMedCentralCrossRefGoogle Scholar
  15. Carman WF, Zanetti AR, Karayiannis P, Waters J, Manzillo G, Tanzi E, et al. Vaccine-induced escape mutant of hepatitis B virus. Lancet. 1990;336(8711):325–9.PubMedCrossRefGoogle Scholar
  16. Carman WF, Trautwein C, van Deursen FJ, Colman K, Dornan E, McIntyre G, et al. Hepatitis B virus envelope variation after transplantation with and without hepatitis B immune globulin prophylaxis. Hepatology. 1996;24(3):489–93.PubMedCrossRefGoogle Scholar
  17. Chan HL-Y, Tsang SW-C, Wong M-L, Tse C-H, Leung NW-Y, Chan FK-L, et al. Genotype B hepatitis B virus is associated with severe icteric flare-up of chronic hepatitis B virus infection in Hong Kong. Am J Gastroenterol. 2002a;97(10):2629–33.PubMedCrossRefGoogle Scholar
  18. Chan HL, Tsang SW, Liew CT, Tse CH, Wong ML, Ching JY, et al. Viral genotype and hepatitis B virus DNA levels are correlated with histological liver damage in HBeAg-negative chronic hepatitis B virus infection. Am J Gastroenterol. 2002b;97(2):406–12.PubMedCrossRefGoogle Scholar
  19. Chen HS, Kew MC, Hornbuckle WE, Tennant BC, Cote PJ, Gerin JL, et al. The precore gene of the woodchuck hepatitis virus genome is not essential for viral replication in the natural host. J Virol. 1992;66(9):5682–4.PubMedPubMedCentralGoogle Scholar
  20. Cheung WI, Chan HL, Leung VK, Tse CH, Fung K, Lin SY, et al. Reactivation of hepatitis B virus infection with persistently negative HBsAg on three HBsAg assays in a lymphoma patient undergoing chemotherapy. J Clin Virol. 2010;47(2):193–5.PubMedCrossRefGoogle Scholar
  21. Chisari FV, Ferrari C. Hepatitis B virus immunopathogenesis. Annu Rev Immunol. 1995;13:29–60.PubMedCrossRefGoogle Scholar
  22. Chu CM, Liaw YF. Intrahepatic distribution of hepatitis B surface and core antigens in chronic hepatitis B virus infection. Hepatocyte with cytoplasmic/membranous hepatitis B core antigen as a possible target for immune hepatocytolysis. Gastroenterology. 1987;92(1):220–5.PubMedCrossRefGoogle Scholar
  23. Colucci G, Beazer Y, Cantaluppi C, Tackney C. Identification of a major hepatitis B core antigen (HBcAg) determinant by using synthetic peptides and monoclonal antibodies. J Immunol. 1988;141(12):4376–80.PubMedGoogle Scholar
  24. Crowther RA, Kiselev NA, Bottcher B, Berriman JA, Borisova GP, Ose V, et al. Three-dimensional structure of hepatitis B virus core particles determined by electron cryomicroscopy. Cell. 1994;77(6):943–50.PubMedCrossRefGoogle Scholar
  25. Decorsiere A, Mueller H, van Breugel PC, Abdul F, Gerossier L, Beran RK, et al. Hepatitis B virus X protein identifies the Smc5/6 complex as a host restriction factor. Nature. 2016;531(7594):386–9.PubMedCrossRefGoogle Scholar
  26. Delaney WE, Locarnini S, Shaw T. Resistance of hepatitis B virus to antiviral drugs: current aspects and directions for future investigation. Antivir Chem Chemother. 2001;12(1):1–35.PubMedCrossRefGoogle Scholar
  27. Desmond CP, Bartholomeusz A, Gaudieri S, Revill PA, Lewin SR. A systematic review of T-cell epitopes in hepatitis B virus: identification, genotypic variation and relevance to antiviral therapeutics. Antivir Ther. 2008;13(2):161–75.PubMedGoogle Scholar
  28. Esteller M. Non-coding RNAs in human disease. Nat Rev Genet. 2011;12(12):861–74.PubMedCrossRefGoogle Scholar
  29. Ferrari C, Bertoletti A, Penna A, Cavalli A, Valli A, Missale G, et al. Identification of immunodominant T cell epitopes of the hepatitis B virus nucleocapsid antigen. J Clin Invest. 1991;88(1):214–22.PubMedPubMedCentralCrossRefGoogle Scholar
  30. Fung SK, Andreone P, Han SH, Rajender Reddy K, Regev A, Keeffe EB, et al. Adefovir-resistant hepatitis B can be associated with viral rebound and hepatic decompensation. J Hepatol. 2005;43(6):937–43.PubMedCrossRefGoogle Scholar
  31. Funk ML, Rosenberg DM, Lok ASF. World-wide epidemiology of HBeAg-negative chronic hepatitis B and associated precore and core promoter variants. J Viral Hepat. 2002;9(1):52–61.PubMedCrossRefGoogle Scholar
  32. Ganem D, Schneider RJ. Hepadnaviridae: the viruses and their replication. In: Knipe DM, Howley PM, editors. Fields virology. 4th ed. Philadelphia: Lippincott Williams & Wilkins; 2001. p. 2923–69.Google Scholar
  33. Gripon P, Le Seyec J, Rumin S, Guguen-Guillouzo C. Myristoylation of the hepatitis B virus large surface protein is essential for viral infectivity. Virology. 1995;213(2):292–9.PubMedCrossRefGoogle Scholar
  34. Gunther S, Fischer L, Pult I, Sterneck M, Will H. Naturally occurring variants of hepatitis B virus. Adv Virus Res. 1999;52:25–2137.PubMedCrossRefGoogle Scholar
  35. Guo L, Wang X, Ren L, Zeng M, Wang S, Weng Y, et al. HBx affects CUL4-DDB1 function in both positive and negative manners. Biochem Biophys Res Commun. 2014;450(4):1492–7.PubMedCrossRefGoogle Scholar
  36. Hadziyannis S. HBeAg-negative chronic hepatitis B: from clinical recognition to pathogenesis and treatment. Viral Hepat Rev. 1995;1:7–l5.Google Scholar
  37. Hadziyannis SJ, Vassilopoulos D. Hepatitis B e antigen-negative chronic hepatitis B. Hepatology. 2001;34(4 Pt 1):617–24.PubMedCrossRefGoogle Scholar
  38. Hayashi S, Murakami S, Omagari K, Matsui T, Iio E, Isogawa M, et al. Characterization of novel entecavir resistance mutations. J Hepatol. 2015;63(3):546–53.PubMedCrossRefGoogle Scholar
  39. Hodgson AJ, Hyser JM, Keasler VV, Cang Y, Slagle BL. Hepatitis B virus regulatory HBx protein binding to DDB1 is required but is not sufficient for maximal HBV replication. Virology. 2012;426(1):73–82.PubMedPubMedCentralCrossRefGoogle Scholar
  40. Hu Z, Zhang Z, Doo E, Coux O, Goldberg AL, Liang TJ. Hepatitis B virus X protein is both a substrate and a potential inhibitor of the proteasome complex. J Virol. 1999;73(9):7231–40.PubMedPubMedCentralGoogle Scholar
  41. Huang J, Kwong J, Sun EC, Liang TJ. Proteasome complex as a potential cellular target of hepatitis B virus X protein. J Virol. 1996;70(8):5582–91.PubMedPubMedCentralGoogle Scholar
  42. Hunt CM, McGill JM, Allen MI, Condreay LD. Clinical relevance of hepatitis B viral mutations. Hepatology. 2000;31(5):1037–44.PubMedCrossRefGoogle Scholar
  43. Kann ML, Gerlich W. Chapter 10: Structure and molecular virology. In: Thomas H, Lemon S, Zuckerman A, editors. Viral hepatitis. Third ed. Oxford, UK: Blackwell Publishing Ltd; 2005.Google Scholar
  44. Kao JH. Hepatitis B viral genotypes: clinical relevance and molecular characteristics. J Gastroenterol Hepatol. 2002;17(6):643–50.PubMedCrossRefGoogle Scholar
  45. Kao JH, Chen DS. Clinical relevance of hepatitis B virus genotypes Ba and Bj in Taiwan. Gastroenterology. 2003;125(6):1916–7. author reply 7–8PubMedCrossRefGoogle Scholar
  46. Koike K, Tsutsumi T, Fujie H, Shintani Y, Kyoji M. Molecular mechanism of viral hepatocarcinogenesis. Oncology. 2002;62(Suppl 1):29–37.PubMedCrossRefGoogle Scholar
  47. Koniger C, Wingert I, Marsmann M, Rosler C, Beck J, Nassal M. Involvement of the host DNA-repair enzyme TDP2 in formation of the covalently closed circular DNA persistence reservoir of hepatitis B viruses. Proc Natl Acad Sci U S A. 2014;111(40):E4244–53.PubMedPubMedCentralCrossRefGoogle Scholar
  48. Lai CL, Dienstag J, Schiff E, Leung NW, Atkins M, Hunt C, et al. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin Infect Dis. 2003;36(6):687–96.PubMedCrossRefGoogle Scholar
  49. Lambert C, Doring T, Prange R. Hepatitis B virus maturation is sensitive to functional inhibition of ESCRT-III, Vps4, and gamma 2-adaptin. J Virol. 2007;81(17):9050–60.PubMedPubMedCentralCrossRefGoogle Scholar
  50. Leupin O, Bontron S, Schaeffer C, Strubin M. Hepatitis B virus X protein stimulates viral genome replication via a DDB1-dependent pathway distinct from that leading to cell death. J Virol. 2005;79(7):4238–45.PubMedPubMedCentralCrossRefGoogle Scholar
  51. Levine S, Hernandez D, Yamanaka G, Zhang S, Rose R, Weinheimer S, et al. Efficacies of entecavir against lamivudine-resistant hepatitis B virus replication and recombinant polymerases in vitro. Antimicrob Agents Chemother. 2002;46(8):2525–32.PubMedPubMedCentralCrossRefGoogle Scholar
  52. Levrero M, Pollicino T, Petersen J, Belloni L, Raimondo G, Dandri M. Control of cccDNA function in hepatitis B virus infection. J Hepatol. 2009;51(3):581–92.PubMedCrossRefGoogle Scholar
  53. Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med. 2004;351(15):1521–31.PubMedCrossRefGoogle Scholar
  54. Liu Y, Li X, Xin S, Xu Z, Chen R, Yang J, et al. The rtA181S mutation of hepatitis B virus primarily confers resistance to adefovir dipivoxil. J Viral Hepat. 2015;22(3):328–34.PubMedCrossRefGoogle Scholar
  55. Locarnini S, Shaw T, Dean J, Colledge D, Thompson A, Li K, et al. Cellular response to conditional expression of the hepatitis B virus precore and core proteins in cultured hepatoma (Huh-7) cells. J Clin Virol. 2005;32(2):113–21.PubMedCrossRefGoogle Scholar
  56. Locarnini S, Littlejohn M, Aziz MN, Yuen L. Possible origins and evolution of the hepatitis B virus (HBV). Semin Cancer Biol. 2013;23(6 Pt B):561–75.PubMedCrossRefGoogle Scholar
  57. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology. 2009;50(3):661–2.PubMedCrossRefGoogle Scholar
  58. Lok AS, Akarca U, Greene S. Mutations in the pre-core region of hepatitis B virus serve to enhance the stability of the secondary structure of the pre-genome encapsidation signal. Proc Natl Acad Sci U S A. 1994;91(9):4077–81.PubMedPubMedCentralCrossRefGoogle Scholar
  59. Lucifora J, Arzberger S, Durantel D, Belloni L, Strubin M, Levrero M, et al. Hepatitis B virus X protein is essential to initiate and maintain virus replication after infection. J Hepatol. 2011;55(5):996–1003.PubMedCrossRefGoogle Scholar
  60. Martin-Vilchez S, Lara-Pezzi E, Trapero-Marugan M, Moreno-Otero R, Sanz-Cameno P. The molecular and pathophysiological implications of hepatitis B X antigen in chronic hepatitis B virus infection. Rev Med Virol. 2011;21(5):315–29.PubMedGoogle Scholar
  61. Matthews GV, Bartholomeusz A, Locarnini S, Ayres A, Sasaduesz J, Seaberg E, et al. Characteristics of drug resistant HBV in an international collaborative study of HIV-HBV-infected individuals on extended lamivudine therapy. AIDS. 2006;20(6):863–70.PubMedCrossRefGoogle Scholar
  62. Meier A, Mehrle S, Weiss TS, Mier W, Urban S. Myristoylated PreS1-domain of the hepatitis B virus L-protein mediates specific binding to differentiated hepatocytes. Hepatology. 2013;58(1):31–42.PubMedCrossRefGoogle Scholar
  63. Milich DR. Genetic and molecular basis for T- and B-cell recognition of hepatitis B viral antigens. Immunol Rev. 1987;99:71–103.PubMedCrossRefGoogle Scholar
  64. Milich DR. T- and B-cell recognition of hepatitis B viral antigens. Immunol Today. 1988;9(12):380–6.PubMedCrossRefGoogle Scholar
  65. Milich DR, Thornton GB, Neurath AR, Kent SB, Michel ML, Tiollais P, et al. Enhanced immunogenicity of the pre-S region of hepatitis B surface antigen. Science. 1985;228(4704):1195–9.PubMedCrossRefGoogle Scholar
  66. Milich DR, McLachlan A, Chisari FV, Kent SB, Thorton GB. Immune response to the pre-S(1) region of the hepatitis B surface antigen (HBsAg): a pre-S(1)-specific T cell response can bypass nonresponsiveness to the pre-S(2) and S regions of HBsAg. J Immunol. 1986;137(1):315–22.PubMedGoogle Scholar
  67. Milich DR, Jones JE, Hughes JL, Price J, Raney AK, McLachlan A. Is a function of the secreted hepatitis B e antigen to induce immunologic tolerance in utero? Proc Natl Acad Sci U S A. 1990;87(17):6599–603.PubMedPubMedCentralCrossRefGoogle Scholar
  68. Minor MM, Slagle BL. Hepatitis B virus HBx protein interactions with the ubiquitin proteasome system. Virus. 2014;6(11):4683–702.CrossRefGoogle Scholar
  69. Missale G, Redeker A, Person J, Fowler P, Guilhot S, Schlicht HJ, et al. HLA-A31- and HLA-Aw68-restricted cytotoxic T cell responses to a single hepatitis B virus nucleocapsid epitope during acute viral hepatitis. J Exp Med. 1993;177(3):751–62.PubMedCrossRefGoogle Scholar
  70. Mutimer D, Pillay D, Cook P, Ratcliffe D, O’Donnell K, Dowling D, et al. Selection of multiresistant hepatitis B virus during sequential nucleoside-analogue therapy. J Infect Dis. 2000;181(2):713–6.PubMedCrossRefGoogle Scholar
  71. Newbold JE, Xin H, Tencza M, Sherman G, Dean J, Bowden S, et al. The covalently closed duplex form of the hepadnavirus genome exists in situ as a heterogeneous population of viral minichromosomes. J Virol. 1995;69(6):3350–7.PubMedPubMedCentralGoogle Scholar
  72. Ni Y, Lempp FA, Mehrle S, Nkongolo S, Kaufman C, Falth M, et al. Hepatitis B and D viruses exploit sodium taurocholate co-transporting polypeptide for species-specific entry into hepatocytes. Gastroenterology. 2014;146(4):1070–83.PubMedCrossRefGoogle Scholar
  73. Noguchi C, Ishino H, Tsuge M, Fujimoto Y, Imamura M, Takahashi S, et al. G to A hypermutation of hepatitis B virus. Hepatology. 2005;41(3):626–33.PubMedCrossRefGoogle Scholar
  74. Norder H, Courouce AM, Magnius LO. Complete genomes, phylogenetic relatedness, and structural proteins of six strains of the hepatitis B virus, four of which represent two new genotypes. Virology. 1994;198(2):489–503.PubMedCrossRefGoogle Scholar
  75. Okamoto H, Tsuda F, Akahane Y, Sugai Y, Yoshiba M, Moriyama K, et al. Hepatitis B virus with mutations in the core promoter for an e antigen-negative phenotype in carriers with antibody to e antigen. J Virol. 1994;68(12):8102–10.PubMedPubMedCentralGoogle Scholar
  76. Olinger CM, Jutavijittum P, Hubschen JM, Yousukh A, Samountry B, Thammavong T, et al. Possible new hepatitis B virus genotype, southeast Asia. Emerg Infect Dis. 2008;14(11):1777–80.  https://doi.org/10.3201/eid1411.080437.PubMedPubMedCentralCrossRefGoogle Scholar
  77. Orito E, Mizokami M, Sakugawa H, Michitaka K, Ishikawa K, Ichida T, et al. A case-control study for clinical and molecular biological differences between hepatitis B viruses of genotypes B and C. Japan HBV Genotype Research Group. Hepatology. 2001;33(1):218–23.PubMedCrossRefGoogle Scholar
  78. Qi X, Xiong S, Yang H, Miller M, Delaney WE. In vitro susceptibility of adefovir-associated hepatitis B virus polymerase mutations to other antiviral agents. Antivir Ther. 2007;12(3):355–62.PubMedGoogle Scholar
  79. Rabe B, Vlachou A, Pante N, Helenius A, Kann M. Nuclear import of hepatitis B virus capsids and release of the viral genome. Proc Natl Acad Sci U S A. 2003;100(17):9849–54.PubMedPubMedCentralCrossRefGoogle Scholar
  80. Rossner MT. Review: Hepatitis B virus X-gene product: a promiscuous transcriptional activator. J Med Virol. 1992;36(2):101–17.PubMedCrossRefGoogle Scholar
  81. Salfeld J, Pfaff E, Noah M, Schaller H. Antigenic determinants and functional domains in core antigen and e antigen from hepatitis B virus. J Virol. 1989;63(2):798–808.PubMedPubMedCentralGoogle Scholar
  82. Scaglioni PP, Melegari M, Wands JR. Posttranscriptional regulation of hepatitis B virus replication by the precore protein. J Virol. 1997;71(1):345–53.PubMedPubMedCentralGoogle Scholar
  83. Schlicht H-J, Bartenschlager R, Schaller H. Biosynthesis and enzymatic functions of the hepadnaviral reverse transcriptase. Molecular biology of the hepatitis B virus. Boca raton: CRC Press; 1991. p. 171–80.Google Scholar
  84. Schulze A, Gripon P, Urban S. Hepatitis B virus infection initiates with a large surface protein-dependent binding to heparan sulfate proteoglycans. Hepatology. 2007;46(6):1759–68.PubMedCrossRefGoogle Scholar
  85. Sheldon J, Camino N, Rodes B, Bartholomeusz A, Kuiper M, Tacke F, et al. Selection of hepatitis B virus polymerase mutations in HIV-coinfected patients treated with tenofovir. Antivir Ther. 2005;10(6):727–34.PubMedGoogle Scholar
  86. Sheldon J, Rodes B, Zoulim F, Bartholomeusz A, Soriano V. Mutations affecting the replication capacity of the hepatitis B virus. J Viral Hepat. 2006;13(7):427–34.PubMedCrossRefGoogle Scholar
  87. Sobotta D, Sominskaya I, Jansons J, Meisel H, Schmitt S, Heermann KH, et al. Mapping of immunodominant B-cell epitopes and the human serum albumin-binding site in natural hepatitis B virus surface antigen of defined genosubtype. J Gen Virol. 2000;81(Pt 2):369–78.PubMedCrossRefGoogle Scholar
  88. Stieler JT, Prange R. Involvement of ESCRT-II in hepatitis B virus morphogenesis. PLoS One. 2014;9(3):e91279.PubMedPubMedCentralCrossRefGoogle Scholar
  89. Stuyver L, De Gendt S, Van Geyt C, Zoulim F, Fried M, Schinazi RF, et al. A new genotype of hepatitis B virus: complete genome and phylogenetic relatedness. J Gen Virol. 2000;81(Pt 1):67–74.PubMedCrossRefGoogle Scholar
  90. Stuyver LJ, Locarnini SA, Lok A, Richman DD, Carman WF, Dienstag JL, et al. Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region. Hepatology. 2001;33(3):751–7.PubMedCrossRefGoogle Scholar
  91. Sureau C, Salisse J. A conformational heparan sulfate binding site essential to infectivity overlaps with the conserved hepatitis B virus a-determinant. Hepatology. 2013;57(3):985–94.PubMedCrossRefGoogle Scholar
  92. Tang KF, Xie J, Chen M, Liu Q, Zhou XY, Zeng W, et al. Knockdown of damage-specific DNA binding protein 1 (DDB1) enhances the HBx-siRNA-mediated inhibition of HBV replication. Biologicals. 2008;36(3):177–83.PubMedCrossRefGoogle Scholar
  93. Tatematsu K, Tanaka Y, Kurbanov F, Sugauchi F, Mano S, Maeshiro T, et al. A genetic variant of hepatitis B virus divergent from known human and ape genotypes isolated from a Japanese patient and provisionally assigned to new genotype J. J Virol. 2009;83(20):10538–47.  https://doi.org/10.1128/JVI.00462-09. Epub 2009 Jul 29PubMedPubMedCentralCrossRefGoogle Scholar
  94. Tenney DJ, Levine SM, Rose RE, Walsh AW, Weinheimer SP, Discotto L, et al. Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine. Antimicrob Agents Chemother. 2004;48(9):3498–507.PubMedPubMedCentralCrossRefGoogle Scholar
  95. Tenney DJ, Rose RE, Baldick CJ, Pokornowski KA, Eggers BJ, Fang J, et al. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy. Hepatology. 2009;49(5):1503–14.PubMedCrossRefGoogle Scholar
  96. Tian Y, Yang W, Song J, Wu Y, Ni B. Hepatitis B virus X protein-induced aberrant epigenetic modifications contributing to human hepatocellular carcinoma pathogenesis. Mol Cell Biol. 2013;33(15):2810–6.PubMedPubMedCentralCrossRefGoogle Scholar
  97. Torresi J. The virological and clinical significance of mutations in the overlapping envelope and polymerase genes of hepatitis B virus. J Clin Virol. 2002;25(2):97–106.PubMedCrossRefGoogle Scholar
  98. Tron F, Degos F, Brechot C, Courouce AM, Goudeau A, Marie FN, et al. Randomized dose range study of a recombinant hepatitis B vaccine produced in mammalian cells and containing the S and PreS2 sequences. J Infect Dis. 1989;160(2):199–204.PubMedCrossRefGoogle Scholar
  99. Tseng TC, Liu CJ, Yang HC, Chen CL, Yang WT, Tsai CS, et al. Higher proportion of viral basal core promoter mutant increases the risk of liver cirrhosis in hepatitis B carriers. Gut. 2015;64(2):292–302.PubMedCrossRefGoogle Scholar
  100. Urban S, Bartenschlager R, Kubitz R, Zoulim F. Strategies to inhibit entry of HBV and HDV into hepatocytes. Gastroenterology. 2014;147(1):48–64.PubMedCrossRefGoogle Scholar
  101. Villet S, Pichoud C, Villeneuve JP, Trepo C, Zoulim F. Selection of a multiple drug-resistant hepatitis B virus strain in a liver-transplanted patient. Gastroenterology. 2006;131(4):1253–61.PubMedCrossRefGoogle Scholar
  102. Villet S, Ollivet A, Pichoud C, Barraud L, Villeneuve JP, Trepo C, et al. Stepwise process for the development of entecavir resistance in a chronic hepatitis B virus infected patient. J Hepatol. 2007;46(3):531–8.PubMedCrossRefGoogle Scholar
  103. Villet S, Pichoud C, Billioud G, Barraud L, Durantel S, Trepo C, et al. Impact of hepatitis B virus rtA181V/T mutants on hepatitis B treatment failure. J Hepatol. 2008;48(5):747–55.PubMedCrossRefGoogle Scholar
  104. Visvanathan K, Skinner NA, Thompson AJ, Riordan SM, Sozzi V, Edwards R, et al. Regulation of Toll-like receptor-2 expression in chronic hepatitis B by the precore protein. Hepatology. 2007;45(1):102–10.PubMedCrossRefGoogle Scholar
  105. Votteler J, Sundquist WI. Virus budding and the ESCRT pathway. Cell Host Microbe. 2013;14(3):232–41.PubMedCrossRefGoogle Scholar
  106. Walsh AW, Langley DR, Colonno RJ, Tenney DJ. Mechanistic characterization and molecular modeling of hepatitis B virus polymerase resistance to entecavir. PLoS One. 2010;5(2):e9195.PubMedPubMedCentralCrossRefGoogle Scholar
  107. Wang XW, Gibson MK, Vermeulen W, Yeh H, Forrester K, Sturzbecher HW, et al. Abrogation of p53-induced apoptosis by the hepatitis B virus X gene. Cancer Res. 1995;55(24):6012–6.PubMedGoogle Scholar
  108. Wang HC, Wu HC, Chen CF, Fausto N, Lei HY, Su IJ. Different types of ground glass hepatocytes in chronic hepatitis B virus infection contain specific pre-S mutants that may induce endoplasmic reticulum stress. Am J Pathol. 2003;163(6):2441–9.PubMedPubMedCentralCrossRefGoogle Scholar
  109. Warner N, Locarnini S. The antiviral drug selected hepatitis B virus rtA181T/sW172* mutant has a dominant negative secretion defect and alters the typical profile of viral rebound. Hepatology. 2008;48(1):88–98.PubMedCrossRefGoogle Scholar
  110. Wieland SF, Chisari FV. Stealth and cunning: hepatitis B and hepatitis C viruses. J Virol. 2005;79(15):9369–80.PubMedPubMedCentralCrossRefGoogle Scholar
  111. Will H, Reiser W, Weimer T, Pfaff E, Buscher M, Sprengel R, et al. Replication strategy of human hepatitis B virus. J Virol. 1987;61(3):904–11.PubMedPubMedCentralGoogle Scholar
  112. Yan H, Peng B, Liu Y, Xu G, He W, Ren B, et al. Viral entry of hepatitis B and D viruses and bile salts transportation share common molecular determinants on sodium taurocholate cotransporting polypeptide. J Virol. 2014;88(6):3273–84.PubMedPubMedCentralCrossRefGoogle Scholar
  113. Yang JC, Teng CF, Wu HC, Tsai HW, Chuang HC, Tsai TF, et al. Enhanced expression of vascular endothelial growth factor-A in ground glass hepatocytes and its implication in hepatitis B virus hepatocarcinogenesis. Hepatology. 2009;49(6):1962–71.PubMedCrossRefGoogle Scholar
  114. Yeh CT, Chien RN, Chu CM, Liaw YF. Clearance of the original hepatitis B virus YMDD-motif mutants with emergence of distinct lamivudine-resistant mutants during prolonged lamivudine therapy. Hepatology. 2000;31(6):1318–26.PubMedCrossRefGoogle Scholar
  115. Yim HJ, Hussain M, Liu Y, Wong SN, Fung SK, Lok AS. Evolution of multi-drug resistant hepatitis B virus during sequential therapy. Hepatology. 2006;44(3):703–12.PubMedCrossRefGoogle Scholar
  116. Zhang XD, Wang Y, Ye LH. Hepatitis B virus X protein accelerates the development of hepatoma. Cancer Biol Med. 2014;11(3):182–90.PubMedPubMedCentralGoogle Scholar
  117. Zhou T, Saputelli J, Aldrich CE, Deslauriers M, Condreay LD, Mason WS. Emergence of drug-resistant populations of woodchuck hepatitis virus in woodchucks treated with the antiviral nucleoside lamivudine. Antimicrob Agents Chemother. 1999;43(8):1947–54.PubMedPubMedCentralGoogle Scholar
  118. Zollner B, Petersen J, Puchhammer-Stockl E, Kletzmayr J, Sterneck M, Fischer L, et al. Viral features of lamivudine resistant hepatitis B genotypes A and D. Hepatology. 2004;39(1):42–50.PubMedCrossRefGoogle Scholar
  119. Zoulim F, Locarnini S. Hepatitis B virus resistance to nucleos(t)ide analogues. Gastroenterology. 2009;137(5):1593–608 e1–2.PubMedCrossRefGoogle Scholar
  120. Zoulim F, Seeger C. Reverse transcription in hepatitis B viruses is primed by a tyrosine residue of the polymerase. J Virol. 1994;68(1):6–13.PubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2018

Authors and Affiliations

  1. 1.Department of GastroenterologySt. Vincent’s Hospital, MelbourneFitzroyAustralia
  2. 2.Department of Molecular Research and DevelopmentVictorian Infectious Diseases Reference LaboratoryMelbourneAustralia

Personalised recommendations